This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Human medicines European public assessment report (EPAR): Skilarence, dimethyl f...
Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, ...
The company revealed a plan to shutter the site back in March of 2022. Now, more...
European Organisation for Research and Treatment of Cancer (EORTC) bilateral mee...
The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 mil...
A trio of drugmakers have issued separate recalls in the U.S. thanks to string o...
David Pacitti is leaving the imaging giant to become CEO of Avanos Medical, afte...
Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, ...
Study results showed Orca’s treatment, a purified mix of donor-derived T cells a...
Human medicines European public assessment report (EPAR): Yervoy, ipilimumab, Da...
In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circl...
Methylphenidate product-specific bioequivelance guidance
2024-2026 Work Plan of the Good Clinical Practice Inspectors Working Group (GCP ...
AstraZeneca has signed two deals worth $1.35 billion with Alteogen to developmen...
The FDA is urging dialysis providers to conserve their supplies of blood flow li...
Novo Nordisk has been accepted back into the fold. Two years after suspending No...
Human medicines European public assessment report (EPAR): Uptravi, selexipag, Da...
How a case involving Dana-Farber Cancer Institute illustrates the potential risk...
This week in health care business news: Dr. Oz will scrutinize Medicare Advantag...
Opko Health and Entera Bio have formalized their partnership as the biotechs pre...
In this tracker, Fierce Pharma is recording the regulatory progress of in-market...
Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, d...